Pharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301].

about

Pharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301].

Item

http://www.wikidata.org/entity/Q38375213

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pharmacokinetics, Pharmacodyna ...... ion at 3 Sites [NCT 02043301].

@en

type

Item

label

Pharmacokinetics, Pharmacodyna ...... ion at 3 Sites [NCT 02043301].

@en

prefLabel

Pharmacokinetics, Pharmacodyna ...... ion at 3 Sites [NCT 02043301].

@en

P1476

Pharmacokinetics, Pharmacodyna ...... ion at 3 Sites [NCT 02043301].

@en

P2093

Anna Plotka

http://www.w3.org/2001/XMLSchema#string

Carla Yunis

http://www.w3.org/2001/XMLSchema#string

Catherine Sattler

http://www.w3.org/2001/XMLSchema#string

Ellen Q Wang

http://www.w3.org/2001/XMLSchema#string

Joanne Salageanu

http://www.w3.org/2001/XMLSchema#string

P2860

PCSK9: a key modulator of cardiovascular health

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.

PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.

Mechanistic determinants of biotherapeutics absorption following SC administration.

A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.

Low-density lipoprotein cholesterol reduction by inhibition of PCSK9.

P31

scholarly article

P356

10.1111/1755-5922.12278

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28636184

http://www.w3.org/2001/XMLSchema#string